Electra Therapeutics raised $183 million to advance its pipeline of SIRP-targeted therapies, including ELA026 for the rare hyperinflammatory disease secondary hemophagocytic lymphohistiocytosis (sHLH), supporting pivotal clinical trials and further development of its novel immune-cell–depleting treatments.
